Antisense Technology
Novosom AG acquires exclusive option for CD40-targeted antisense inhibitors from Isis Pharmaceuticals
Published in Gene Therapy Weekly, May 3rd, 2007
Novosom AG today announced that it has purchased an exclusive option from Isis Pharmaceuticals, Inc. that, if exercised within six months, enables it to acquire an exclusive, worldwide license to antisense inhibitors targeting the CD40 membrane protein for all indications. CD40 is a validated target for both inflammatory diseases and B-cell cancers and Novosom plans to target CD40 for indications such as Crohn's disease, transplant, rheumatoid arthritis, cancer and multiple sclerosis. If acquired, the license from Isis would include rights to the target and to oligonucleotides targeting CD40 and incorporating Isis' second generation antisense chemistry, 2' MOE oligonucleotides in exchange...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2007-05-03)
More Articles from Gene Therapy Weekly
- Cancer Gene Therapy
Gelatin-Based Nanoparticle Effective in Gene Therapy for Breast Cancer - Cancer Gene Therapy
Intravenous nanoparticle gene therapy shows activity in stage IV lung cancer - Cancer Vaccines
Breast cancer vaccine stimulates potent immune response to cancer cells - Antisense Technology
Lorus Therapeutics Announces Scientific Presentations for Lead Antisense and siRNA Drug Candidates at International Cancer Conference - Cord Blood
Cryo-Cell Names Two Officers to Key Scientific, Marketing Positions - Gene Therapy
Calando Pharmaceuticals Announces Preclinical Efficacy and Safety Data of Targeted, Systemic Delivery of siRNA at AACR Annual Meeting - More from this issue of Gene Therapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
